“Myelodysplastic Syndrome Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelodysplastic Syndrome Market.
The Myelodysplastic Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Myelodysplastic Syndrome Pipeline Report:
- Companies across the globe are diligently working toward developing novel Myelodysplastic Syndrome treatment therapies with a considerable amount of success over the years.
- Myelodysplastic Syndrome companies working in the treatment market are Amgen, Chia Tai Tianqing Pharmaceutical Group, Ryvu Therapeutics SA, Sanofi, Agios Pharmaceuticals, Curis, Forma Therapeutics, Syros Pharmaceuticals, Novartis, FibroGe, AbbVie, Syros Pharmaceuticals, Gilead Sciences, Geron Corporation, Takeda, Pfizer, and others, are developing therapies for the Myelodysplastic Syndrome treatment
- Emerging Myelodysplastic Syndrome therapies in the different phases of clinical trials are- AMG 176, TQB2618, RVU120, SAR443579, AG-946, CA-4948, Etavopivat, Tamibarotene, MBG453, roxadustat, Venclexta ± azacitidine, sabatolimab, SY-1425 + azacitidine, magrolimab ± azacitidine, imetelstat, pevonedistat ± azacitidine, glasdegib + azacitidine, and others are expected to have a significant impact on the Myelodysplastic Syndrome market in the coming years.
- In March 2022, For patients with intermediate, high, or very high risk myelodysplastic syndrome (MDS) according to IPSS-R criteria (US Multi-centre), Novartis started a single-arm, open-label, Phase II study of MBG453 (sabatolimab) added to FDA-approved hypomethylating agents of the investigator’s choice (IV, SC, or oral) (STIMULUS MDS-US)
- In August 2021, According to clinical data showing a high rate of responses in patients with high-risk MDS who were treated with sabatolimab in combination with hypomethylating agents (HMAs), Novartis announced that the European Commission (EC) had granted Orphan Drug Designation to sabatolimab (MBG453) for the treatment of myelodysplastic syndromes (MDS).
Myelodysplastic Syndrome Overview
A heterogeneous category of hematologic neoplasms known as myelodysplastic syndrome (MDS) is characterised by dysplasia and inefficient hematopoiesis in the bone marrow as a result of clonal disorders of hematopoietic stem cells. Acute myeloid leukaemia (AML) can convert in some patients with MDS.
Get a Free Sample PDF Report to know more about Myelodysplastic Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight
Emerging Myelodysplastic Syndrome Drugs Under Different Phases of Clinical Development Include:
- AMG 176: Amgen
- TQB2618: Chia Tai Tianqing Pharmaceutical Group
- RVU120: Ryvu Therapeutics SA
- SAR443579: Sanofi
- AG-946: Agios Pharmaceuticals
- CA-4948: Curis
- Etavopivat: Forma Therapeutics
- Tamibarotene: Syros Pharmaceuticals
- MBG453: Novartis
- roxadustat: FibroGe
- Venclexta ± azacitidine: AbbVie
- sabatolimab: Novartis
- SY-1425 + azacitidine: Syros Pharmaceuticals
- magrolimab ± azacitidine: Gilead Sciences
- imetelstat: Geron Corporation
- pevonedistat ± azacitidine: Takeda
- glasdegib + azacitidine: Pfizer
Myelodysplastic Syndrome Route of Administration
Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Myelodysplastic Syndrome Molecule Type
Myelodysplastic Syndrome Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Myelodysplastic Syndrome Pipeline Therapeutics Assessment
- Myelodysplastic Syndrome Assessment by Product Type
- Myelodysplastic Syndrome By Stage and Product Type
- Myelodysplastic Syndrome Assessment by Route of Administration
- Myelodysplastic Syndrome By Stage and Route of Administration
- Myelodysplastic Syndrome Assessment by Molecule Type
- Myelodysplastic Syndrome by Stage and Molecule Type
DelveInsight’s Myelodysplastic Syndrome Report covers around 150+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Myelodysplastic Syndrome product details are provided in the report. Download the Myelodysplastic Syndrome pipeline report to learn more about the emerging Myelodysplastic Syndrome therapies
Some of the key companies in the Myelodysplastic Syndrome Therapeutics Market include:
Key companies developing therapies for Myelodysplastic Syndrome are – Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac, and others.
Myelodysplastic Syndrome Pipeline Analysis:
The Myelodysplastic Syndrome pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Myelodysplastic Syndrome with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome Treatment.
- Myelodysplastic Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Myelodysplastic Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelodysplastic Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myelodysplastic Syndrome drugs and therapies
Myelodysplastic Syndrome Pipeline Market Drivers
- Increasing Prevalence of Myelodysplastic Syndromes, increase in research and developmental activities are some of the important factors that are fueling the Myelodysplastic Syndrome Market.
Myelodysplastic Syndrome Pipeline Market Barriers
- However, high-cost associated with the disease, poor diagnosis of the disease and other factors are creating obstacles in the Myelodysplastic Syndrome Market growth.
Scope of Myelodysplastic Syndrome Pipeline Drug Insight
- Coverage: Global
- Key Myelodysplastic Syndrome Companies: Amgen, Chia Tai Tianqing Pharmaceutical Group, Ryvu Therapeutics SA, Sanofi, Agios Pharmaceuticals, Curis, Forma Therapeutics, Syros Pharmaceuticals, Novartis, FibroGe, AbbVie, Syros Pharmaceuticals, Gilead Sciences, Geron Corporation, Takeda, Pfizer, and others
- Key Myelodysplastic Syndrome Therapies: AMG 176, TQB2618, RVU120, SAR443579, AG-946, CA-4948, Etavopivat, Tamibarotene, MBG453, roxadustat, Venclexta ± azacitidine, sabatolimab, SY-1425 + azacitidine, magrolimab ± azacitidine, imetelstat, pevonedistat ± azacitidine, glasdegib + azacitidine, and others
- Myelodysplastic Syndrome Therapeutic Assessment: Myelodysplastic Syndrome current marketed and Myelodysplastic Syndrome emerging therapies
- Myelodysplastic Syndrome Market Dynamics: Myelodysplastic Syndrome market drivers and Myelodysplastic Syndrome market barriers
Request for Sample PDF Report for Myelodysplastic Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Myelodysplastic Syndrome Report Introduction
2. Myelodysplastic Syndrome Executive Summary
3. Myelodysplastic Syndrome Overview
4. Myelodysplastic Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Myelodysplastic Syndrome Pipeline Therapeutics
6. Myelodysplastic Syndrome Late Stage Products (Phase II/III)
7. Myelodysplastic Syndrome Mid Stage Products (Phase II)
8. Myelodysplastic Syndrome Early Stage Products (Phase I)
9. Myelodysplastic Syndrome Preclinical Stage Products
10. Myelodysplastic Syndrome Therapeutics Assessment
11. Myelodysplastic Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myelodysplastic Syndrome Key Companies
14. Myelodysplastic Syndrome Key Products
15. Myelodysplastic Syndrome Unmet Needs
16 . Myelodysplastic Syndrome Market Drivers and Barriers
17. Myelodysplastic Syndrome Future Perspectives and Conclusion
18. Myelodysplastic Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services